MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

BACKGROUND: Most ALK-positive lung cancers will develop ALK-independent resistance after treatment with next-generation ALK inhibitors. MET amplification has been described in patients progressing on ALK inhibitors, but frequency of this event has not been comprehensively assessed. METHODS: We perfo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Dagogo-Jack, Ibiayi, Yoda, Satoshi, Lennerz, Jochen K., Langenbucher, Adam, Lin, Jessica J., Rooney, Marguerite, Prutisto-Chang, Kylie, Oh, Audris, Adams, Nathaniel A., Yeap, Beow Y., Chin, Emily, Do, Andrew, Marble, Hetal D., Stevens, Sara E., Digumarthy, Subba R., Saxena, Ashish, Nagy, Rebecca J., Benes, Cyril H., Azzoli, Christopher G., Lawrence, Michael, Gainor, Justin F., Shaw, Alice T., Hata, Aaron N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7269872/
https://ncbi.nlm.nih.gov/pubmed/32086345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3906
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados